Abstract Number: 0037 • ACR Convergence 2025
A Proteomic Signature Containing TNF Receptor Superfamily Member 10A (TNFRSF10A) and Growth/Differentiation Factor 15 (GDF-15) Improves Prediction of All-Cause Mortality Among Individuals with Gout, Beyond Atherosclerotic Cardiovascular and Other Clinical Risk Factors
Background/Purpose: Gout affects >12 million US adults and is associated with premature all-cause and cardiovascular (CV) mortality which has failed to improve over recent decades,…Abstract Number: 0088 • ACR Convergence 2025
Imbalance of Inflammation-Regulating Microorganisms and Predicted Metabolomic Pathways Associates With Disease Evolution in Individuals At-Risk for Rheumatoid Arthritis
Background/Purpose: The mucosal origins hypothesis of RA proposes that immune responses to microorganisms at mucosal sites (e.g. intestine) lead to systemic inflammation and autoimmunity. Little…Abstract Number: 0006 • ACR Convergence 2025
QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis
Background/Purpose: Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc) are immune mediated inflammatory diseases (IMID) where a complex interplay of tissue and immune cell activation drives…Abstract Number: 0094 • ACR Convergence 2025
Distinct immune-molecular signatures modulated ex vivo by JAK and TNF predict Rheumatoid Arthritis therapy outcomes in patients naïve to biologic and targeted synthetic DMARDs
Background/Purpose: Despite advances in rheumatoid arthritis (RA) treatment, 20–40% of patients do not respond to biologic or targeted synthetic DMARDs (b/tsDMARDs). Understanding each drug’s molecular…Abstract Number: 0028 • ACR Convergence 2025
Computational and Laboratory Identification of Risk-Driving Alleles on Juvenile Idiopathic Arthritis (JIA)-Associated Haplotypes
Background/Purpose: Multiple genomic regions are known to confer risk for JIA. However, identifying the SNPs that exert the biological effects that confer risk, and therefore…Abstract Number: 0077 • ACR Convergence 2025
Transformer-based multi-omics study identifies important role of glycine, serine and threonine metabolism pathway in rheumatoid arthritis complicated by anemia
Background/Purpose: Anemia is a prevalent hematologic complication of rheumatoid arthritis (RA) that exacerbates the disease process and severely impacts clinical performance and treatment strategies. We…Abstract Number: 0095 • ACR Convergence 2025
Effect of JAK Inhibitors on Osteoblast Differentiation
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation and joint destruction. Among the therapeutic strategies available, Janus kinase (JAK) inhibitors have…Abstract Number: 0139 • ACR Convergence 2025
When One Isn’t Enough: Does Adding IgM Worsen the Antiphospholipid Syndrome Phenotype?
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by the persistent presence of antiphospholipid antibodies (aPL) along with clinical manifestations such as venous…Abstract Number: 0141 • ACR Convergence 2025
Cytokine profiles in antiphospholipid syndrome
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with unknown etiology. Inflammatory-mediated tissue damage plays an important role in APS. This study aimed to investigate…Abstract Number: 0072 • ACR Convergence 2025
Impact of Baricitinib on Cardiovascular Health in Biologic-naïve Rheumatoid Arthritis patients: A Comparative Study with TNF Inhibitors and Conventional DMARDs
Background/Purpose: Therapeutic advances in RA have introduced effective treatments, including b/tsDMARDs such as Baricitinib. However, its cardiovascular safety profile remains unclear, partly due to the…Abstract Number: 0040 • ACR Convergence 2025
Identification Of A Novel, Expressed, Alternatively Spliced FCER1G Protein That Inhibits Receptor Function
Background/Purpose: The Tyrosine Activation Motif (ITAM)-containing FcRg chain, encoded by FCER1G, non-covalently couples with the immunoglobulin binding receptors, -- FcγRI (CD64), FcγRIIIa (CD16), and FcaRI…Abstract Number: 0121 • ACR Convergence 2025
The Prevalence and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibody Isotypes in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Registry
Background/Purpose: The 2023 ACR/EULAR Antiphospholipid Syndrome (APS) Classification Criteria (CC) focus on IgG and IgM anticardiolipin (aCL) and anti-β2-glycoprotein-I antibodies (aβ2GPI). IgA isotypes were excluded…Abstract Number: 0122 • ACR Convergence 2025
The role of low profile antiphospholipid antibodies and adverse pregnancy outcomes.
Background/Purpose: Presence of high titer antiphospholipid antibodies (aPLs) confer adverse pregnancy outcomes (APOs). Patients with low titer aPLs often receive conflicting counseling on treatment, many…Abstract Number: 0054 • ACR Convergence 2025
Microbial Cues Promote Arthritis and Alter T Cell Selection in SKG Mice
Background/Purpose: Dysbiosis of the gut microbiota has been linked to rheumatoid arthritis (RA), but it remains unclear whether these microbial alterations are causal or secondary…Abstract Number: 0104 • ACR Convergence 2025
Dissecting the Genetic and Functional Association of CARD9 with Axial Spondyloarthritis
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic immune-mediated inflammatory disease with strong genetic predisposition, driven by HLA-B27 and over 100 additional loci identified by genome-wide…
- « Previous Page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- …
- 2607
- Next Page »